265 related articles for article (PubMed ID: 16135026)
21. Sequential designs for ordinal phase I clinical trials.
Liu G; Rosenberger WF; Haines LM
Biom J; 2009 Apr; 51(2):335-47. PubMed ID: 19358220
[TBL] [Abstract][Full Text] [Related]
22. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
23. Dose escalation trial designs based on a molecularly targeted endpoint.
Hunsberger S; Rubinstein LV; Dancey J; Korn EL
Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
[TBL] [Abstract][Full Text] [Related]
24. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
He W; Liu J; Binkowitz B; Quan H
Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
[TBL] [Abstract][Full Text] [Related]
25. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
Faries D
J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
[TBL] [Abstract][Full Text] [Related]
26. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
Daimon T; Zohar S; O'Quigley J
Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
[TBL] [Abstract][Full Text] [Related]
27. Two-sample continual reassessment method.
O'Quigley J; Shen LZ; Gamst A
J Biopharm Stat; 1999 Mar; 9(1):17-44. PubMed ID: 10091908
[TBL] [Abstract][Full Text] [Related]
28. The continual reassessment method for dose-finding studies: a tutorial.
Garrett-Mayer E
Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.
Legedza AT; Ibrahim JG
Stat Med; 2001 Mar; 20(6):867-82. PubMed ID: 11252009
[TBL] [Abstract][Full Text] [Related]
30. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities.
Braun TM
Stat Med; 2006 Jun; 25(12):2071-83. PubMed ID: 16217853
[TBL] [Abstract][Full Text] [Related]
31. A two-stage dose selection strategy in phase I trials with wide dose ranges.
Wang O; Faries DE
J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
[TBL] [Abstract][Full Text] [Related]
32. Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.
Yin G; Zheng S; Xu J
J Biopharm Stat; 2013; 23(4):856-70. PubMed ID: 23786314
[TBL] [Abstract][Full Text] [Related]
33. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
34. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
35. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
36. Improved up-and-down designs for phase I trials.
Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
[TBL] [Abstract][Full Text] [Related]
37. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
38. A Bayesian dose finding design for dual endpoint phase I trials.
Loke YC; Tan SB; Cai Y; Machin D
Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
[TBL] [Abstract][Full Text] [Related]
39. Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.
Fan SK; Wang YG
Stat Med; 2006 May; 25(10):1699-714. PubMed ID: 16217860
[TBL] [Abstract][Full Text] [Related]
40. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]